Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Companion Diagnostics

Dan Rhodes's Biography

Dan Rhodes, Head of Oncology Strategy, Thermo Fisher Scientific

Dr. Rhodes is a specialist in cancer genomics and is most recently published in Cancer Discovery on ““Identification of targetable FGFR gene fusions in diverse cancers.” He commercialized the Oncomine™ database by co-founding Compendia Bioscience with Dr. Arul Chinnaiyan in 2006. Now as part of Thermo Fisher Scientific, Dr. Rhodes continues to develop cancer diagnostics through genomic analysis as Head of Oncology Strategy for the company. Dr. Rhodes has received several awards for his work including the Harold Weintraub Award and the Team Science Award from the AACR, and he maintains a part-time faculty research position at The University of Michigan Center for Translational Pathology. Dr. Rhodes received both a Bachelor of Science in Molecular Biology and a Doctorate in Bioinformatics and Cancer Biology from The University of Michigan, Ann Arbor.

Dan Rhodes Image

A Unified Approach to NGS-based Oncology Companion Diagnostics Development

Tuesday, 28 October 2014 at 11:00

Add to Calendar ▼2014-10-28 11:00:002014-10-28 12:00:00Europe/LondonA Unified Approach to NGS-based Oncology Companion Diagnostics

There is significant interest from pharmaceutical and regulatory communities, alike, for the development toward a multi-marker companion diagnostic product to support the increasing number of potential targeted therapeutic candidates that may address small cancer sub-populations. Traditionally, pharmaceutical and diagnostic development partners have designed individual companion diagnostic products for each therapeutic candidate, however this has proven costly, time-consuming and is increasingly impractical in the marketplace as the number of targeted therapies and individual companion tests grow.  To aid in addressing these challenges, we developed the Oncomine® Cancer Research Panel*, an NGS panel targeting 143 genes, capable of accurately detecting the majority of genetic biomarkers associated with on market therapies and investigational-targeted therapies. Classes of genetic alterations detected include mutations, copy number variants, indels, and gene fusions. Retrospective and prospective research studies demonstrating the value of the panel will be described. In addition, our efforts to partner with the pharmaceutical community to help design clinical trial strategies supporting multiple drug candidates will be discussed.
*For Research Use Only.  Not for use in diagnostic procedures.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonCompanion